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Objectives. We sought to determine the influence of plaque
morphology and warfarin anticoagulation on the risk of recurrent
emboli in patients with mobile aortic atheroma.
Background. An epidemiologic link between aortic atheroma
and systemic emboli has been described both in pathologic and
transesophageal studies. Likewise, a few studies have found an
increased incidence of recurrent emboli in these patients. The
therapeutic implications of these findings has not been studied.
Methods. Thirty-one patients presenting with a systemic em-
bolic event and found to have mobile aortic atheroma were
studied. The height, width and area of both immobile and mobile
portions of atheroma were quantitated. The dimensions of the
mobile component was used to define three groups: small, inter-
mediate and large mobile atheroma. The patients were followed
up by means of telephone interview and clinical records, with
emphasis on anticoagulant use and recurrent embolic or vascular
events.
Results. Patients not receiving warfarin had a higher incidence
of vascular events (45% vs. 5%, p 5 0.006). Stroke occurred in 27%
of these patients and in none of those treated with warfarin. The
annual incidence of stroke in patients not taking warfarin was
0.32. Myocardial infarction occurred in 18% of patients also in
this group. Taken together, the risk of myocardial infarction or
stroke was significantly increased in this group (p 5 0.001).
Forty-seven percent of patients with small, mobile atheroma did
not receive warfarin. Recurrent stroke occurred in 38% of these
patients, representing an annual incidence of 0.61. There were no
strokes in patients with small, mobile atheroma treated with
warfarin (p 5 0.04). Likewise, none of the patients with interme-
diate or large mobile atheroma had a stroke during follow-up.
Only three of these patients had not been taking warfarin.
Conclusions. Patients presenting with systemic emboli and
found to have mobile aortic atheroma on transesophageal echo-
cardiography have a high incidence of recurrent vascular events.
Warfarin is efficacious in preventing stroke in this population.
The dimension of the mobile component of atheroma should not
be used to determine the need for anticoagulation.
(J Am Coll Cardiol 1998;31:134–8)
©1998 by the American College of Cardiology
Nearly 40 years have passed since the aorta was first recog-
nized as a source for systemic emboli (1). For most of this
period, clinically available studies such as computed tomogra-
phy and angiography could not assess the integrity of aortic
endothelium well. Consequently, clinical studies of aortic
atheroma were unfeasible until transesophageal echocardiog-
raphy (TEE) was introduced in 1977. Using high fidelity TEE
imaging, several investigators have reappraised the link be-
tween aortic atheroma and systemic emboli (2–19). As in
pathologic reports (1,20–22), an increased frequency of prom-
inent aortic atheroma was almost universally described. Pro-
truding atheroma and those containing mobile components
have been associated with high embolic potential. These data
not only implicate atheroma in the genesis of emboli but also
infer the need for therapy once they are identified. Although
thrombus has been suspected as the major constituent of
embolic material originating from atheroma, no studies report-
ing on the efficacy of antithrombotic therapy in preventing
recurrent emboli have appeared. Thus, the therapeutic impli-
cations of high risk atheroma remain unknown. Several cases
of fatal systemic embolization apparently induced by anticoag-
ulant therapy have been reported (23–26). These reports,
combined with the hemorrhagic risks of warfarin, have resulted
in a therapeutic quandary for the clinician.
The purpose of the present study was to describe the
influence of morphologic plaque features and antithrombotic
therapy on the risk of recurrent emboli in patients with mobile
aortic atheroma.
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Methods
Study group. The study group was derived from the 1,390
patients who presented with systemic emboli and underwent
TEE at our institution since 1987. The criterion for inclusion
was the presence of plaque in the thoracic aorta that contained
a mobile component. Mobility was defined as movement
independent of the motion of the aortic wall. In-hospital
records were reviewed for atherosclerotic risk factors, diseases,
cerebral ischemic symptoms and subsequent evaluation. All
diagnostic test results were reviewed. Patients presenting with
cerebral ischemia and found to have significant ipsilateral
carotid artery narrowing ($60% diameter) were excluded. The
suspected side of cerebral ischemia was determined by history
or brain scanning, or both. Patients presenting with sudden left
hemiparesis, hemiplegia or hemihypesthesia were considered
to have had a right cerebral infarction. Patients with aphasia
were also suspected of having a left-sided lesion if they were
right-handed. Neurovascular ultrasound of the extracerebral
and intracerebral arteries was performed in each patient.
Those with significant narrowing of a suspect cerebral artery
were excluded. Patients in whom symptoms and brain scanning
failed to identify a likely cerebral arterial distribution were
excluded if one of the cerebral arteries was significantly
narrowed. Those with plaques distal to the origin of the left
subclavian artery were excluded unless peripheral embolus was
the presenting symptom.
Of the 1,390 patients undergoing TEE for systemic emboli,
108 (7.8%) had high risk aortic plaque (protruding $5 mm or
mobile, or both). Of these 108 patients, 31 had mobile plaque
and fulfilled entry criteria and they form the study group.
There were 18 men (56%) and 13 women (44%) (Table 1). The
patients’ mean age was 66 6 10 years and was similar in men
(66 6 11 years) and women (66 6 10 years). Stroke was the
most common presenting symptom. One or more risk factors
for atherosclerosis were present in 28 (90%) and two or more
in 19 (61%) of the group (mean 1.8 6 1.0 per patient).
Hypertension (74%) and tobacco smoking (45%) were most
frequent. One or more clinically apparent atherosclerotic
disease processes (narrowing of one or more systemic arteries)
were present in 20 patients (60%): a single site in 10 (32%) and
two or more sites in 10 (32%) (mean 1.0 6 0.8 per patient).
Coronary artery narrowing was most frequent (39%), followed
by contralateral carotid artery disease (26%), peripheral vas-
cular disease (19%) and aneurysm of the abdominal aorta
(10%). One or more atherosclerotic risk factors or symptom-
atic atherosclerotic disease, or both, were identified in 30
(96%) of 31 patients.
Of the 31 study patients, 25 (81%) presented with cerebro-
vascular emboli and 6 (19%) with peripheral emboli. Of the 25
patients presenting with cerebrovascular emboli, a suspected
arterial distribution was determined by symptoms or computed
tomography or magnetic resonance imaging, or a combination
of these, in 22. In three patients, the symptoms were vague and
cerebral scanning failed to detect an acute infarct. As defined
by the exclusion criteria, none of the study patients had
significant lumen narrowing (.60%) in a suspect cerebral
artery on neurovascular ultrasonography (n 5 27) or angiog-
raphy (n 5 4).
Transesophageal echocardiography. All TEE was per-
formed with a 5-MHz probe. Multiplane probes were used in
the majority of studies (53%). Complete examinations of the
heart and thoracic aorta were obtained. Each study included a
short- or long-axis view, or both, of the ascending, transverse
and descending portions of the thoracic aorta. The largest
plaque located in a region of the aorta that could have caused
the patient’s embolic symptoms was selected for quantitative
measurement. Short-axis measurement of plaque was obtained
only when the imaging plane was thought to be perpendicular
to the long axis of the aorta. Likewise, long-axis views were
obtained only when the imaging plane appeared to bisect the
aortic cylinder. Once the best short- and long-axis images were
selected, each plaque was divided into immobile and mobile
portions (Fig. 1). The height, width and area of these compo-
nents were measured in both short- and long-axis views using
proprietary computer software. Height was defined as the
greatest dimension in a plane perpendicular to the adjacent
aortic wall. Width was defined as the greatest dimension in a
plane parallel to the adjacent aortic wall. Plaque mobility was
quantitated by measurement of greatest excursion (in degrees)
during one cardiac cycle. The patients were further subclassi-
fied into groups according to the mobile component size: 1)
small 5 diameter #1 mm; intermediate 5 diameter .1 mm
and area ,10 mm2; and 3) large 5 diameter .1 mm and area
$10 mm2.
Anticoagulant therapy and follow-up. The choice of anti-
coagulant therapy was determined by the referring physician.
Of the 31 study patients, 20 (65%) received long-term warfarin
Table 1. Baseline Clinical Characteristics
Age (yr) 66 6 10
Men 18 (58%)
Women 13 (42%)
Presenting symptom
Stroke 18 (58%)
TIA 7 (23%)
Peripheral emboli 6 (19%)
Atherosclerosis
Risk factors
HTN 26 (74%)
Tobacco smoking 14 (45%)
Diabetes mellitus 10 (32%)
Cholesterolemia 4 (13%)
Family history 5 (16%)
Extraaortic site 20 (65%)
CAD 12 (39%)
Carotid artery narrowing 8 (26%)
PVD 6 (19%)
AAA 3 (10%)
Data presented are mean value 6 SD or number (%) of patients. AAA 5
aneurysm of abdominal aorta; CAD 5 coronary artery disease; HTN 5
hypertension; PVD 5 peripheral vascular disease; TIA 5 transient ischemic
attack.
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therapy. Warfarin was initiated within 1 week of hospital
admission and was adjusted to maintain an international
normalized ratio of 2.0. The 11 patients (35%) not receiving
warfarin were treated with aspirin (n 5 7) or received no
anticoagulant agent (n 5 4). Follow-up included telephone
interview and review of subsequent hospital admissions. The
duration of warfarin and antiplatelet therapy (either ticlid or
aspirin) was noted. End points included vascular events
(stroke, transient ischemic attack, myocardial infarction) and
death. All strokes during the follow-up period were confirmed
by computed tomography and or magnetic resonance imaging.
Statistics. The clinical and morphologic features of pa-
tients treated with and without warfarin were compared using
unpaired t tests and contingency table analysis. The influence
of plaque morphologic appearance on recurrent emboli was
compared using contingency table analysis.
Results
Plaque dimensions. The mean height, width and area of
the immobile component of atheroma were 6.6 6 3.1 mm,
25.8 6 11.6 mm and 108 6 57 mm2, respectively, and of the
mobile component, 8.1 6 9.6 mm, 3.0 6 3.1 mm and 42 6 76
mm2, respectively. The mean excursion of the mobile compo-
nent during the cardiac cycle was 83 6 57°. When the groups
with and without warfarin were compared, no significant
differences in the immobile component of atheroma were
found: height 6.9 6 3.4 vs. 6.2 6 2.5 mm; width 24.7 6 12.0 vs.
27.6 6 11.1 mm; and area 108 6 76 vs. 108 6 57 mm2.
Although not reaching statistical significance, trends toward a
larger mobile component were seen in the group treated with
warfarin: height 9.5 6 11.0 vs. 5.5 6 4.1 mm (p 5 0.27); width
3.6 6 3.5 vs. 1.8 6 1.4 mm (p 5 0.12); and area 56 6 91 vs.
16 6 10 mm2 (p 5 0.16). The mobility of atheroma was similar
between the groups with and without warfarin (83 6 58° vs.
85 6 57°, p 5 NS).
Morphologic groups. The 31 patients with mobile plaques
were classified according to morphologic plaque characteris-
tics, as delineated in the Methods section. There were 17
patients (55%) with small, 10 (32%) with intermediate and 4
(13%) with large, mobile atheroma. Although height did not
reach statistical significance, the width and area of the immo-
bile component were paradoxically less than those in the large,
mobile group compared with the intermediate or small, mobile
groups. By definition, each group differed significantly with
regard to the mobile component dimension. The degree of
excursion (mobility) of the three morphologic groups was
similar (95 6 67° vs. 69 6 47° vs. 71 6 29°, respectively, p 5
NS).
Potential cardiac sources of emboli. In 16 patients (52%),
TEE identified one or more potential cardiac embolic sources
in addition to aortic atheroma. The treatment groups (with vs.
without warfarin) were similar with regard to the frequency of
these findings: patent foramen ovale and/or atrial septal aneu-
rysm (27% vs. 25%); atrial fibrillation (0% vs. 5%); dense left
atrial spontaneous contrast (0% vs. 5%); and left atrial ap-
Figure 1. TEE short-axis image (A) and schematic (B) demonstrating
quantitation of immobile components of atheroma (cross-hatched
area).
Figure 2. TEE short-axis image (A) and schematic (B) demonstrating
quantitation of mobile components of atheroma (cross-hatched area).
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pendage thrombus (0% vs. 5%). Patients receiving warfarin
tended to have a higher frequency of akinetic or severely
hypokinetic left ventricular segments (9% vs. 35%, p 5 0.11).
Events during follow-up. The mean interval from TEE to
follow-up was similar between patients treated with warfarin
and those going without it (9.5 6 8.7 vs. 10.8 6 9.7 months, p 5
NS). Of the 11 patients not treated with warfarin, 3 (27%) had
strokes (Table 2). None of those receiving warfarin had a
stroke (p 5 0.07). The annual incidence of stroke in patients
not receiving warfarin was 0.32. Myocardial infarction oc-
curred in two patients, neither of whom had received warfarin.
Taken together, the risk for either stroke or myocardial
infarction (45%) was significantly increased in this group (p 5
0.006). There were four deaths: one from stroke in the group
not receiving warfarin and three among patients receiving
warfarin (sudden cardiac death, gastrointestinal bleed and
cancer) (p 5 NS).
Morphologic groups and recurrent stroke. The influence
of anticoagulation on recurrent stroke in the three morpho-
logic groups is presented in Table 3. Of the 17 patients in
whom small, mobile plaques were identified, 8 (47%) did not
receive warfarin. Recurrent stroke occurred in 3 (38%) of
these patients, representing an annual incidence of 0.61. Each
of these patients had received long-term aspirin therapy and
were taking aspirin (325 mg/day) at the time of the stroke. No
strokes occurred in patients with small, mobile atheroma
treated with warfarin (p 5 0.04). Likewise, none of the 14
patients with intermediate (n 5 10) or large (n 5 4), mobile
atheroma had a stroke during follow-up. Only 3 (21%) of these
patients had not been treated with warfarin.
Discussion
Although several investigators have described the epidemi-
ologic association between atheroma and systemic emboli both
as an index (2–19) and recurrent event (27,28), few studies are
available on the appropriate anticoagulant choice in these
patients. In the present study, we found that patients with
mobile atheroma not treated with warfarin were at high risk
(27%) of recurrent stroke. Furthermore, it appears that the
morphologic findings on TEE may have influenced the antico-
agulant choice. Of patients with intermediate or large, mobile
atheroma, only 21% were not placed on warfarin therapy. In
contrast, nearly half (47%) of those with small, mobile plaques
were not given warfarin. It is likely that the small size of the
atheroma persuaded some clinicians to avoid warfarin. The
inadequacy of this strategy is underscored by the 38% stroke
rate in this group. In contrast, in patients with intermediate or
large, mobile atheroma, clinicians most often chose warfarin
anticoagulation. None of these patients had recurrent stroke.
Although our data are insufficient to describe the embolic risk
of patients with larger atheroma who do not receive warfarin,
it appears this form of anticoagulation effectively prevents
stroke in these atheroma morphologies. These results suggest
that mobile atheroma should be anticoagulated with warfarin
and that the dimension of plaque should not be used to
determine therapy.
Plaque morphology and recurrent events. Although the
efficacy of therapy has not been previously described, other
studies have described morphologic features of atheroma
associated with recurrent events. In a prospective study of
patients found to have protruding and/or mobile aortic ather-
oma on TEE, Tunick et al. (27) identified a 33% embolic event
rate during a mean follow-up period of 13 months. In a study
of 331 patients with brain infarction, the French Study of
Aortic Plaques in Stroke Group (28) found that high risk
plaque ($4 mm thick) had a recurrent (mean follow-up 2.4
years) stroke rate of 11.9 in 100 person-years. After adjusting
for confounding factors, this high risk plaque represented a
relative risk of 3.8 compared with more benign-appearing
plaques (,1 mm thick). Neither of these studies describes the
influence of anticoagulant therapy on the risk of recurrent
embolic events. In our study, the annual stroke risk of patients
with mobile atheroma not treated with warfarin was 0.32 (32 in
100 person-years). The differences in risk identified in our
patients may be due not only to therapeutic choices but also to
differences in plaque morphologies. Our data are limited to
patients with mobile plaque. Although not elucidated, it may
be expected that the majority of patients in the aforemen-
tioned studies (27,28) did not have mobile atheroma.
Paradoxic emboli after anticoagulation. In addition to its
implications regarding long-term therapy of mobile atheroma,
our study challenges commonly held views on the appropriate
treatment immediately after the initial embolic event. Classic
clinical teaching has suggested caution in treating patients with
suspected atheromatous emboli with systemic anticoagulation
(29). These recommendations, however, are based on very
Table 2. Plaque Dimensions
Immobile component
Height (mm) 6.6 6 3.1
Width (mm) 25.8 6 11.6
Area (mm2) 108 6 63
Mobile component
Height (mm) 8.1 6 9.6
Width (mm) 3.0 6 3.1
Area (mm2) 42 6 76
Mobility (degrees) 83 6 57
Data presented are mean value 6 SD.
Table 3. Aortic Atheroma: Follow-Up Events
Event
Warfarin
(n 5 20)
No Warfarin
(n 5 11) p Value
Vascular 1 (5%) 5 (45%) 0.006
Stroke 0 3 (27%) 0.07
MI 0 2 (18%) NS
SD 1 (5%) 0 NS
Death 3 (15%) 1 (9%) NS
Vascular event or death 4 (20%) 5 (45%) 0.14
Data presented are number (%) of patients. MI 5 myocardial infarction;
SD 5 sudden death.
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limited data primarily consisting of case reports (23–26). The
hypothesis is that anticoagulation will result in “cholesterol”
embolization and the so-called “blue toe” syndrome. Our
report appears to contradict this practice and would suggest
that systemic anticoagulation is certainly not contraindicated,
but rather should be the treatment of choice in such patients.
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